Cargando…
The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatm...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874864/ https://www.ncbi.nlm.nih.gov/pubmed/33603621 http://dx.doi.org/10.5114/ada.2020.96705 |
_version_ | 1783649674378346496 |
---|---|
author | Waszczykowski, Michał Bednarski, Igor Lesiak, Aleksandra Waszczykowska, Elżbieta Narbutt, Joanna Fabiś, Jarosław |
author_facet | Waszczykowski, Michał Bednarski, Igor Lesiak, Aleksandra Waszczykowska, Elżbieta Narbutt, Joanna Fabiś, Jarosław |
author_sort | Waszczykowski, Michał |
collection | PubMed |
description | INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA. MATERIAL AND METHODS: The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated. RESULTS: The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment (p = 0.00018 for IL-6; p = 0.01242 for MMP-1; p = 0.03263 for YKL-40). CONCLUSIONS: IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment. |
format | Online Article Text |
id | pubmed-7874864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-78748642021-02-17 The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients Waszczykowski, Michał Bednarski, Igor Lesiak, Aleksandra Waszczykowska, Elżbieta Narbutt, Joanna Fabiś, Jarosław Postepy Dermatol Alergol Original Paper INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA. MATERIAL AND METHODS: The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated. RESULTS: The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment (p = 0.00018 for IL-6; p = 0.01242 for MMP-1; p = 0.03263 for YKL-40). CONCLUSIONS: IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment. Termedia Publishing House 2020-07-14 2020-12 /pmc/articles/PMC7874864/ /pubmed/33603621 http://dx.doi.org/10.5114/ada.2020.96705 Text en Copyright: © 2020 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Waszczykowski, Michał Bednarski, Igor Lesiak, Aleksandra Waszczykowska, Elżbieta Narbutt, Joanna Fabiś, Jarosław The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title | The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title_full | The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title_fullStr | The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title_full_unstemmed | The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title_short | The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
title_sort | influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874864/ https://www.ncbi.nlm.nih.gov/pubmed/33603621 http://dx.doi.org/10.5114/ada.2020.96705 |
work_keys_str_mv | AT waszczykowskimichał theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT bednarskiigor theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT lesiakaleksandra theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT waszczykowskaelzbieta theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT narbuttjoanna theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT fabisjarosław theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT waszczykowskimichał influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT bednarskiigor influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT lesiakaleksandra influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT waszczykowskaelzbieta influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT narbuttjoanna influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients AT fabisjarosław influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients |